Wray C, Sojka W J, Morris J A, Brinley Morgan W J
J Hyg (Lond). 1977 Aug;79(1):17-24. doi: 10.1017/s0022172400052803.
A galactose epimeraseless (gal E) mutant of Salmonella typhimurium was investigated in mice and calves for its suitability as a live vaccine. In mice, a very highly significant difference in the mortality rates was observed when vaccinated and non-vaccinated animals were challenged with virulent strains of S. typhimurium and S. dublin. In calves, doses of 10(6) and above of gal E mutant injected subcutaneously provided highly significant protection both in terms of mortality and prevalence of symptoms when calves were challenged orally with S. typhimurium. However, there appeared to be a relation between the vaccine and the presence of renal lesions and before gal E mutants can be recommended, further work is necessary to determine the pathogenesis of these lesions.
对鼠伤寒沙门氏菌的一种无半乳糖差向异构酶(gal E)突变体进行了研究,以考察其作为活疫苗在小鼠和犊牛中的适用性。在小鼠中,用鼠伤寒沙门氏菌和都柏林沙门氏菌的强毒株攻击接种和未接种动物时,观察到死亡率有非常显著的差异。在犊牛中,当犊牛经口感染鼠伤寒沙门氏菌时,皮下注射10(6)及以上剂量的gal E突变体在死亡率和症状发生率方面均提供了高度显著的保护作用。然而,疫苗与肾损伤的存在之间似乎存在关联,在推荐使用gal E突变体之前,有必要开展进一步工作以确定这些损伤的发病机制。